We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Elecsys Androstenedione Immunoassay Evaluated and Compared

By LabMedica International staff writers
Posted on 20 May 2022
Print article
Image: The new Elecsys Androstenedione assay has been compared and evaluated (Photo courtesy of Blood Tests London)
Image: The new Elecsys Androstenedione assay has been compared and evaluated (Photo courtesy of Blood Tests London)

Androstenedione (ASD) is a biomarker used in the diagnostic workup of hyperandrogenism, congenital adrenal hyperplasia, premature adrenarche, and polycystic ovary syndrome (PCOS). Androstenedione is the precursor of testosterone and estrone and is produced in the gonads and adrenal glands.

Along with other sex hormones, ASD is essential for the onset and development of sexual differentiation in males and females. ASD measurement in serum or plasma is used to assess adrenal and gonadal function and steroid hormone biosynthesis deficiency. A new ASD competitive electrochemiluminescence immunoassay has been evaluated.

Medical Laboratory Scientists at the Cleveland Clinic (Cleveland, OH, USA) evaluated the linearity/analytical measuring range (AMR), precision, and accuracy of the Elecsys ASD assay on the cobas e601 analyzer (Roche Diagnostics, Indianapolis, IN, USA). For comparison, the Immulite ASD was performed using the Immulite 2000 (Siemens Medical Solutions USA, Inc. Malvern, PA, USA). Specimens were sent to a reference laboratory for analysis by LC-MS/MS. The scientists used 40 specimens (33 sera and seven plasma samples) for the method comparison studies The Elecsys ASD assay is an 18-minute competitive electrochemiluminescence immunoassay that utilizes ASD-specific biotinylated monoclonal antibodies and ruthenium complex-conjugated ASD for ASD assessment.

The investigators reported that the Elecsys ASD assay had a linear response across the AMR. The intra- and inter-assay coefficients of variation at various concentrations were ≤4.5%. The Elecsys ASD assay had a mean difference of −0.04 ng/mL (−1.7%) with the LC-MS/MS assay, whereas the Immulite assay had a mean difference of 1.17 ng/mL (66%) and −1.22 ng/mL (−38%) compared to the LC-MS/MS and Elecsys ASD assays, respectively. The Roche recommended RIs for healthy men (0.280–1.52 ng/mL) and postmenopausal women (0.187–1.07 ng/mL) were successfully verified. The RIs for children were adopted from published data. For pre-menopausal women, a RI of <1.60 ng/mL was established. The ASD concentrations in women with and without PCOS overlapped.

The authors concluded that the Elecsys ASD assay has excellent precision, specificity, and accuracy. It offers many advantages over the Immulite ASD assay and is a suitable alternative for ASD measurement in clinical laboratories. However, the assay should be thoroughly validated before its use for clinical testing and reference intervals established for the patient population, as needed. The Elecsys ASD assay has superior comparability to the LC-MS/MS assay than the Immulite assay. The study was published on May 10, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Cleveland Clinic 
Roche Diagnostics 
Siemens Medical Solutions USA 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.